AXLA Документы SEC - Axcella Health Inc.- Годовой отчет, доверенное заявление, проспект эмиссии

Основная статистика

CIK

1633070

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Axcella Health Inc.

SEC Filings (Chronological Order)

На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.

December 22, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 21, 2023 AXCELLA HEALTH UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 21, 2023 AXCELLA HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-38901 26-3321056 (State or other jurisdiction of incorporation) (Commission F
December 19, 2023	8-K	Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 5, 2023 AXCELLA HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-38901 26-3321056 (State or other jurisdiction of incorporation) (Commission Fi
December 4, 2023	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 4, 2023 AXCELLA HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-38901 26-3321056 (State or other jurisdiction of incorporation) (Commission Fi
November 17, 2023	S-8 POS	As filed with the Securities and Exchange Commission on November 17, 2023 As filed with the Securities and Exchange Commission on November 17, 2023 Registration No.
November 17, 2023	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 16, 2023 AXCELLA HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-38901 26-3321056 (State or other jurisdiction of incorporation) (Commission F
November 17, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi
November 17, 2023	S-8 POS	As filed with the Securities and Exchange Commission on November 17, 2023 As filed with the Securities and Exchange Commission on November 17, 2023 Registration No.
November 9, 2023	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2023 AXCELLA HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-38901 26-3321056 (State or other jurisdiction of incorporation) (Commission Fi
November 6, 2023	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi
November 1, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2023 AXCELLA HEALTH I UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2023 AXCELLA HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-38901 26-3321056 (State or other jurisdiction of incorporation) (Commission Fi
November 1, 2023	EX-2.1	PLAN OF LIQUIDATION AND DISSOLUTION OF Axcella HEALTH INC. Exhibit 2.1 PLAN OF LIQUIDATION AND DISSOLUTION OF Axcella HEALTH INC. This Plan of Liquidation and Dissolution (the “Plan”) is intended to accomplish the complete liquidation and dissolution of AXCELLA HEALTH INC., a Delaware corporation (such corporation or a successor entity, the “Company”), in accordance with Section 281(b) of the General Corporation Law of the State of Delaware (the “DGCL”).
October 6, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 3, 2023 AXCELLA HEALTH IN UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 3, 2023 AXCELLA HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-38901 26-3321056 (State or other jurisdiction of incorporation) (Commission Fil
September 18, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 18, 2023 AXCELLA HEALTH UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 18, 2023 AXCELLA HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-38901 26-3321056 (State or other jurisdiction of incorporation) (Commission
September 18, 2023	EX-3.1	CERTIFICATE OF AMENDMENT RESTATED CERTIFICATE OF INCORPORATION AXCELLA HEALTH INC. Exhibit 3.1 CERTIFICATE OF AMENDMENT TO RESTATED CERTIFICATE OF INCORPORATION OF AXCELLA HEALTH INC. Axcella Health Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Corporation”), does hereby certify as follows: FIRST: That the Board of Directors of the Corporation duly adopted resolutions recommending and declaring advisa
September 18, 2023	EX-4.1	THIS CERTIFIES THAT is the owner of CUSIP DATED COUNTERSIGNED AND REGISTERED: COMPUTERSHARE TRUST COMPANY, N.A. TRANSFER AGENT AND REGISTRAR, COMMON STOCK PAR VALUE $0.001 COMMON STOCK SEE REVERSE FOR CERTAIN DEFINITIONS Certificate Number Shares .. Exhibit 4.1 THIS CERTIFIES THAT is the owner of CUSIP DATED COUNTERSIGNED AND REGISTERED: COMPUTERSHARE TRUST COMPANY, N.A. TRANSFER AGENT AND REGISTRAR, COMMON STOCK PAR VALUE $0.001 COMMON STOCK SEE REVERSE FOR CERTAIN DEFINITIONS Certificate Number Shares .. President & CEO Senior Vice President, Chief Legal Officer and Secretary By AUTHORIZED SIGNATURE AXCELLA HEALTH INC. INCORPORATED UNDER TH
September 14, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 14, 2023 AXCELLA HEALTH UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 14, 2023 AXCELLA HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-38901 26-3321056 (State or other jurisdiction of incorporation) (Commission
September 14, 2023	EX-99.1	– AXLA common stock expected to begin trading on a split-adjusted basis on September 19, 2023 – Exhibit 99.1 Axcella Announces Reverse Stock Split Effective September 19, 2023 – AXLA common stock expected to begin trading on a split-adjusted basis on September 19, 2023 – CAMBRIDGE, Mass.-(BUSINESS WIRE)-Sep. 14, 2023- Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company focused on pioneering a new approach to address the biology of complex diseases using compositions o
September 11, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 11, 2023 AXCELLA HEALTH UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 11, 2023 AXCELLA HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-38901 26-3321056 (State or other jurisdiction of incorporation) (Commission
August 29, 2023	EX-99.1	Axcella Granted Patent for Long COVID Fatigue Treatment Claims cover methods of treating a subject presenting with fatigue from post-acute sequelae of COVID-19 (PASC), a/k/a Long COVID, with Candidate AXA1125 Exhibit 99.1 Axcella Granted Patent for Long COVID Fatigue Treatment Claims cover methods of treating a subject presenting with fatigue from post-acute sequelae of COVID-19 (PASC), a/k/a Long COVID, with Candidate AXA1125 CAMBRIDGE, Mass.—August 29, 2023 - Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company focused on pioneering a new approach to address the biology of comp
August 29, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 29, 2023 AXCELLA HEALTH IN UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 29, 2023 AXCELLA HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-38901 26-3321056 (State or other jurisdiction of incorporation) (Commission Fil
August 18, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rul
August 7, 2023	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rul
August 4, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2023 AXCELLA HEALTH INC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2023 AXCELLA HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-38901 26-3321056 (State or other jurisdiction of incorporation) (Commission File
August 3, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2023 AXCELLA HEALTH INC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2023 AXCELLA HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-38901 26-3321056 (State or other jurisdiction of incorporation) (Commission File
August 3, 2023	EX-99.1	Axcella Reports Second Quarter Financial Results and Provides Business Update Exhibit 99.1 Axcella Reports Second Quarter Financial Results and Provides Business Update •AXA1125 remains the most advanced product to help patients experiencing fatigue post acute COVID-19 •The Company continues to pursue a strategic alternative for stakeholders Cambridge, Mass., August 3, 2023 – Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company focused on pioneering a
August 3, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ______________________________________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER: 001-38901 AXC
June 29, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2023 AXCELLA HEALTH INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2023 AXCELLA HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-38901 26-3321056 (State or other jurisdiction of incorporation) (Commission File
May 4, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ______________________________________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-38501 AXC
May 4, 2023	EX-99.1	Axcella Reports First Quarter Financial Results and Provides Business Update Exhibit 99.1 Axcella Reports First Quarter Financial Results and Provides Business Update •Long COVID Phase 2b/3 clinical trial may proceed under U.S. Investigational New Drug application •MHRA guidance aligns on key measurements for a Long COVID registration trial, including primary endpoint and trial design elements •Lancet eClinical Medicine published findings from the Phase 2a clinical trial o
May 4, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2023 AXCELLA HEALTH INC. ( UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2023 AXCELLA HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-38901 26-3321056 (State or other jurisdiction of incorporation) (Commission File Nu
April 7, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 3, 2023 AXCELLA HEALTH INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 3, 2023 AXCELLA HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-38901 26-3321056 (State or other jurisdiction of incorporation) (Commission File
March 30, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2023 AXCELLA HEALTH INC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2023 AXCELLA HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-38901 26-3321056 (State or other jurisdiction of incorporation) (Commission File
March 30, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ______________________________________________________________________________ ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Fo Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-38501 AXCELLA
March 30, 2023	EX-22.1	Subsidiaries of the Registrant Exhibit 21.1 List of Subsidiaries Subsidiary Jurisdiction of incorporation or organization Acora Nutrition LLC Delaware Axcella Health Securities Corporation Massachusetts
March 30, 2023	EX-99.1	Axcella Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update Exhibit 99.1 Axcella Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update •Long COVID Phase 2b/3 study may proceed under U.S. Investigational New Drug application •MHRA guidance aligns on key measurements for a Long COVID registration trial, including primary endpoint and trial design elements •Axcella presented at Long COVID forum co-sponsored by BIO and Solve
February 17, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2023 AXCELLA HEALTH UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2023 AXCELLA HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-38901 26-3321056 (State or other jurisdiction of incorporation) (Commission F
February 17, 2023	EX-10.3	Retention Agreement, dated February 14, 2023, by and between Axcella Health Inc. and Paul Fehlner. Exhibit 10.3 Axcella Health Inc. P.O. Box 1270 Littleton, MA 01460 Letter Agreement for Retention and to Amend Employment Agreement February 14, 2023 Confidential Paul Fehlner 125 Brookside Avenue Ridgewood NJ 07450 Dear Paul: The purpose of this letter agreement (“Letter Agreement”) is to provide an incentive for you to continue employment with Axcella Health Inc. (“Axcella” or “the Company”)1 du
February 17, 2023	EX-10.2	Retention Agreement, dated February 14, 2023, by and between Axcella Health Inc. and Margaret Koziel. Exhibit 10.2 Axcella Health Inc. P.O. Box 1270 Littleton, MA 01460 Letter Agreement for Retention and to Amend Employment Agreement February 14, 2023 Confidential Margaret Koziel 198 Washington Avenue Needham, MA 02492 Dear Margaret: The purpose of this letter agreement (“Letter Agreement”) is to provide an incentive for you to continue employment with Axcella Health Inc. (“Axcella” or “the Compan
February 17, 2023	EX-10.1	Retention Agreement, dated February 14, 2023, by and between Axcella Health Inc. and William Hinshaw. Exhibit 10.1 Axcella Health Inc. P.O. Box 1270 Littleton, MA 01460 Letter Agreement for Retention and to Amend Employment Agreement February 14, 2023 Confidential William Hinshaw 451 Marlborough Street Unit 5 Boston, MA 02115 Dear Bill: The purpose of this letter agreement (“Letter Agreement”) is to provide an incentive for you to continue employment with Axcella Health Inc. (“Axcella” or “the Com
February 14, 2023	SC 13G/A	AXLA / Axcella Health Inc / HarbourVest Partners L.P. - SC 13G/A Passive Investment SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Axcella Health Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 05454B105 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pur
February 2, 2023	SC 13G/A	AXLA / Axcella Health Inc / Societe des Produits Nestle S.A. - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4) Axcella Health Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 05454B105 (CUSIP Number) Nestlé S.A. Avenue Nestlé, 55 1800 Vevey Switzerland Attention: General Counsel Facsimile: 011-41-21-924-2821 with a copy
January 4, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 30, 2022 AXCELLA HEALTH UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 30, 2022 AXCELLA HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-38901 26-3321056 (State or other jurisdiction of incorporation) (Commission F
December 15, 2022	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Costs Associated with Exit or Disposal Activities, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2022 AXCELLA HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-38901 26-3321056 (State or other jurisdiction of incorporation) (Commission F
December 15, 2022	EX-99.1	Axcella Announces Program Reprioritization and Corporate Restructuring Move Positions Company to Best Focus on Long COVID Program Exhibit 99.1 Axcella Announces Program Reprioritization and Corporate Restructuring Move Positions Company to Best Focus on Long COVID Program CAMBRIDGE, Mass., December 14, 2022 ? Axcella Therapeutics (Nasdaq: AXLA), a biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announces a repositioning of
November 1, 2022	EX-10.2	First Amendment to Securities Purchase Agreement, dated as of September 30, 2022, by and among Axcella Health Inc. and the purchasers party thereto. Exhibit 10.2 FIRST AMENDMENT TO SECURITIES PURCHASE AGREEMENT This First Amendment to Securities Purchase Agreement (this ?Amendment?) is made and entered into as of September 30, 2022, and amends the Securities Purchase Agreement (the ?Agreement?) dated as of September 20, 2022 by and among Axcella Health Inc., a Delaware corporation (?Company?) and the purchasers who executed a counterparty sign
November 1, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2022 AXCELLA HEALTH I UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2022 AXCELLA HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-38901 26-3321056 (State or other jurisdiction of incorporation) (Commission Fi
November 1, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ______________________________________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-38501
November 1, 2022	EX-99.1	Axcella Reports Third Quarter Financial Results and Provides Business Update Exhibit 99.1 Axcella Reports Third Quarter Financial Results and Provides Business Update •Promising Results from Phase 2a Placebo Controlled Clinical Trial for Long COVID •Positive Interim Data from Phase 2b EMMPACT Study of AXA1125 in Nonalcoholic Steatohepatitis (NASH) •$34.2 Million Registered Direct Offering of Common Stock Priced At The Market •Appointment of Two New Board Members Cambridge,
October 17, 2022	EX-99.1	JOINT FILING AGREEMENT Exhibit 99.1 CUSIP No. 05454B105 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13D may be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge
October 17, 2022	SC 13D/A	AXLA / Axcella Health Inc / Flagship VentureLabs IV, LLC - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 4)* AXCELLA HEALTH INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 05454B105 (CUSIP Number) Noubar B. Afeyan, Ph.D. Flagship Pioneering 55 Cambridge Parkway, Suite 800E Cambridge, MA 02142 (617) 868-1888 (Name, Address and Tel
October 13, 2022	EX-99.1	1 Exhibit 99.1 Axcella Therapeutics Announces $34.2 Million Registered Direct Offering of Common Stock Priced At The Market: Appoints Two New Board Members CAMBRIDGE, Mass., October 13, 2022 ? Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today ann
October 13, 2022	424B5	20,847,888 Shares Common stock TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-238983 Prospectus Supplement (To prospectus dated June 12, 2020) 20,847,888 Shares Common stock We are offering 20,847,888 shares of our common stock, with a par value of $0.001 per share for an issue price of $1.64 per share in a registered direct offering directly to investors pursuant to this prospectus supplement and the
October 13, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 10, 2022 AXCELLA HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-38901 26-3321056 (State or other jurisdiction of incorporation) (Commission Fi
October 13, 2022	EX-10.1	Form of Securities Purchase Agreement dated as of October 13, 2022 by and among Axcella Health, Inc. and the purchasers thereto (Incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K (File No. 001-38901) filed with the Securities and Exchange Commission on October 13, 2022). Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of October 13, 2022, between Axcella Health Inc., a Delaware corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively the ?Purchasers?). WHEREAS, subject to the terms and conditions s
September 29, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 29, 2022 AXCELLA HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-38901 26-3321056 (State or other jurisdiction of incorporation) (Commission
September 29, 2022	EX-99.2	© 2022 Axcella Therapeutics. All rights reserved. NASDAQ: AXLA AXA1125 - 101 Interim Analysis September 29, 2022 Exhibit 99.2 ? 2022 Axcella Therapeutics. All rights reserved. NASDAQ: AXLA AXA1125 - 101 Interim Analysis September 29, 2022 ? 2022 Axcella Therapeutics. All rights reserved. 2 Forward - Looking Statements This presentation contains forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 , as amended, including, without limitation, statements regard
September 29, 2022	EX-99.1	Axcella Announces Positive Interim Data from Phase 2b EMMPACT Study of AXA1125 in Nonalcoholic Steatohepatitis (NASH) Subjects enrolled with biopsy confirmed NASH experienced clinically and statistically significant improvements in liver stiffness as Exhibit 99.1 Axcella Announces Positive Interim Data from Phase 2b EMMPACT Study of AXA1125 in Nonalcoholic Steatohepatitis (NASH) Subjects enrolled with biopsy confirmed NASH experienced clinically and statistically significant improvements in liver stiffness as measured by FibroScan, a non-invasive measure of liver fibrosis Subjects with NASH experienced clinically and statistically significant
September 23, 2022	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 20, 2022 AXCELLA HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-38901 26-3321056 (State or other jurisdiction of incorporation) (Commission
September 23, 2022	EX-10.2	Form of Convertible Promissory Note (Incorporated by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K (File No. 001-38901) filed with the Securities and Exchange Commission on September 23, 2022). Exhibit 10.2 THE OBLIGATIONS EVIDENCED BY THIS CONVERTIBLE PROMISSORY NOTE ARE EXPRESSLY SUBORDINATED TO THE OBLIGATIONS (AS DEFINED IN THAT CERTAIN LOAN AND SECURITY AGREEMENT, DATED SEPTEMBER 2, 2021, BY AND BETWEEN THE COMPANY (AS DEFINED BELOW) AND SLR INVESTMENT CORP. (THE ?LOAN AND SECURITY AGREEMENT?)) IN ACCORDANCE WITH THE TERMS OF THAT CERTAIN SUBORDINATION AGREEMENT, DATED SEPTEMBER 20,
September 23, 2022	EX-99.1	JOINT FILING AGREEMENT Exhibit 99.1 CUSIP No. 05454B105 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13D may be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge
September 23, 2022	SC 13D/A	AXLA / Axcella Health Inc / Flagship VentureLabs IV, LLC - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3)* AXCELLA HEALTH INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 05454B105 (CUSIP Number) Noubar B. Afeyan, Ph.D. Flagship Pioneering 55 Cambridge Parkway, Suite 800E Cambridge, MA 02142 (617) 868-1888 (Name, Address and Tel
September 23, 2022	EX-10.1	purchasers (Incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K (File No. 001-38901) filed with the Securities and Exchange Commission on September 23, 2022). Exhibit 10.1 THE NOTES (AS DEFINED BELOW) PURCHASED PURSUANT TO THIS AGREEMENT ARE EXPRESSLY SUBORDINATED TO THE OBLIGATIONS (AS DEFINED IN THAT CERTAIN LOAN AND SECURITY AGREEMENT, DATED SEPTEMBER 2, 2021, BY AND BETWEEN THE COMPANY (AS DEFINED BELOW) AND SLR INVESTMENT CORP.) IN ACCORDANCE WITH THE TERMS OF THAT CERTAIN SUBORDINATION AGREEMENT, DATED SEPTEMBER 20, 2022, BY AND AMONG THE CREDITOR
August 12, 2022	EX-99.1	Axcella Reports Second Quarter Financial Results and Provides Business Update Exhibit 99.1 Axcella Reports Second Quarter Financial Results and Provides Business Update ?Announced Statistically Significant Clinical Improvement in Fatigue in the Phase 2A Long COVID Trial Topline data ?NASH Trial interim Data Expected in Late Q3 2022 ?Company to Host Conference Call at 8:30 a.m. ET today Cambridge, Mass., August 12, 2022 ? Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage
August 12, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ______________________________________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-38501 AXCE
August 12, 2022	EX-10.1	Employment Agreement, by and between the Company and Daniel Kirby, dated as of May 26, 2022. Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (?Agreement?) is made as of the 26th Day of May 2022 between Axcella Health Inc., doing business as Axcella Therapeutics, a Delaware corporation (the ?Company?), and Daniel Kirby (the ?Executive?). WHEREAS, the Company and the Executive are parties to an Employment Agreement dated as of February 16, 2021 (the ?Prior Agreement?); WHEREAS,
August 12, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2022 AXCELLA HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-38901 26-3321056 (State or other jurisdiction of incorporation) (Commission Fil
August 2, 2022	EX-99.2	© 2022 Axcella Therapeutics. All rights reserved. NASDAQ: AXLA Axcella Therapeutics Phase 2A Long COVID Study Results Presentation Bill Hinshaw , President and CEO, Axcella August 2022 Exhibit 99.2 © 2022 Axcella Therapeutics. All rights reserved. NASDAQ: AXLA Axcella Therapeutics Phase 2A Long COVID Study Results Presentation Bill Hinshaw , President and CEO, Axcella August 2022 © 2022 Axcella Therapeutics. All rights reserved. 2 Forward - Looking Statements This presentation contains forward - looking statements within the meaning of the Private Securities Litigation Reform Ac
August 2, 2022	EX-99.1	Axcella Announces Highly Promising Results from Phase 2a Placebo Controlled Clinical Trial for Long COVID Subjects with Long COVID receiving AXA1125 experienced a clinically and statistically significant improvement in mental (p=0.0097) and physical Exhibit 99.1 Axcella Announces Highly Promising Results from Phase 2a Placebo Controlled Clinical Trial for Long COVID Subjects with Long COVID receiving AXA1125 experienced a clinically and statistically significant improvement in mental (p=0.0097) and physical (p=0.0097) fatigue scores compared to placebo subjects Responders to AXA1125 demonstrated significantly improved scores during a 6 minute
August 2, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2022 AXCELLA HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-38901 26-3321056 (State or other jurisdiction of incorporation) (Commission File
May 26, 2022	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 26, 2022 AXCELLA HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-38901 26-3321056 (State or other jurisdiction of incorporation) (Commission File N
May 26, 2022	EX-99.1	# # # Exhibit 99.1 Axcella Announces Completion of Enrollment of Clinical Trial for Long COVID and Has Prioritized its Clinical Portfolio ? Long COVID Trial Topline data expected in early Q3 2022 ? NASH Trial interim data expected in late Q3 2022 ? OHE Trial Suspended CAMBRIDGE, Mass. ? May 26, 2022 ? Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach t
May 25, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2022 AXCELLA HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-38901 26-3321056 (State or other jurisdiction of incorporation) (Commission File N
May 5, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2022 AXCELLA HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-38901 26-3321056 (State or other jurisdiction of incorporation) (Commission File Nu
May 5, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ______________________________________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-38501 AXC
May 5, 2022	EX-99.1	Axcella Reports First Quarter Financial Results and Provides Business Update Exhibit 99.1 Axcella Reports First Quarter Financial Results and Provides Business Update Cambridge, Mass., May 5, 2022 ? Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced financial results for the first quarter ended March 31, 2022 a
April 7, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin
April 7, 2022	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ????) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitted by R
March 30, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2022 AXCELLA HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-38901 26-3321056 (State or other jurisdiction of incorporation) (Commission File
March 30, 2022	EX-21.1	Subsidiaries of the Registrant Exhibit 21.1 List of Subsidiaries Subsidiary Jurisdiction of incorporation or organization Acora Nutrition LLC Delaware Axcella Health Securities Corporation Massachusetts
March 30, 2022	EX-99.1	Axcella Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update Exhibit 99.1 Axcella Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update ?Completed $25 million registered direct stock offering priced at the market ?Initiated Phase 2a Long COVID clinical trial ?Fast Track designation received from FDA for AXA1125 in NASH with liver fibrosis ?Enhanced management team ?Long COVID top-line data and NASH interim dat
March 30, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ______________________________________________________________________________ ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Fo Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-38501 AXCELLA
March 29, 2022	SC 13G/A	AXLA / Axcella Health Inc / HarbourVest Partners L.P. - SC 13G/A Passive Investment SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Axcella Health Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 05454B105 (CUSIP Number) March 16, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua
March 18, 2022	SC 13D/A	AXLA / Axcella Health Inc / Flagship VentureLabs IV, LLC - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* AXCELLA HEALTH INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 05454B105 (CUSIP Number) Noubar B. Afeyan, Ph.D. Flagship Pioneering 55 Cambridge Parkway, Suite 800E Cambridge, MA 02142 (617) 868-1888 (Name, Address and Tel
March 18, 2022	EX-99.1	JOINT FILING AGREEMENT Exhibit 99.1 CUSIP No. 05454B105 JOINT FILING AGREEMENT The persons below hereby agree that the Schedule 13D to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13D, shall be filed jointly on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Dated: March
March 18, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 18, 2022 (March 16, 2022) AXCELLA HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-38901 26-3321056 (State or other jurisdiction of incorporation)
March 16, 2022	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 16, 2022 AXCELLA HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-38901 26-3321056 (State or other jurisdiction of incorporation) (Commission File
March 16, 2022	EX-99.1	Axcella Therapeutics Announces $25 Million Registered Direct Offering of Common Stock Priced At the Market Exhibit 99.1 Axcella Therapeutics Announces $25 Million Registered Direct Offering of Common Stock Priced At the Market Cambridge, Mass., March 16, 2022 ? Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that it has entered into a se
March 16, 2022	EX-10.1	Form of Securities Purchase Agreement dated as of March 16, 2022 by and among Axcella Health, Inc. and the purchasers thereto Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of March 16, 2022, between Axcella Health Inc., a Delaware corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively the ?Purchasers?). WHEREAS, subject to the terms and conditions set
March 16, 2022	424B5	13,089,002 Shares Common stock TABLE OF CONTENTS ?Filed Pursuant to Rule 424(b)(5) ?Registration No. 333-238983? Prospectus Supplement (To prospectus dated June 12, 2020) 13,089,002 Shares Common stock We are offering 13,089,002 shares of our common stock, with a par value of $0.001 per share for an issue price of $1.91 per share in a registered direct offering directly to investors pursuant to this prospectus supplement and th
February 7, 2022	EX-99.1	Axcella Therapeutics Announces Appointment of New Chief Financial Officer Exhibit 99.1 Axcella Therapeutics Announces Appointment of New Chief Financial Officer Cambridge, Mass., February 7, 2022 ? Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced the appointment of Robert Crane as the company?s new Chief F
February 7, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 7, 2022 AXCELLA HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-38901 26-3321056 (State or other jurisdiction of incorporation) (Commission Fi
February 7, 2022	EX-10.1	Employment Agreement, by and between the Company and Robert Crane, dated as of January 24, 2022. Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (?Agreement?) is made as of the 24th Day of January 2022 between Axcella Health Inc., a Delaware corporation (the ?Company?), and Robert Crane (the ?Executive?). WHEREAS, the Company desires to employ the Executive and the Executive desires to be employed by the Company on the terms and conditions contained herein commencing on February 8
January 10, 2022	EX-99.1	© 2022 Axcella Therapeutics. All rights reserved. NASDAQ: AXLA Axcella Therapeutics Investor Presentation January 2022 © 2022 Axcella Therapeutics. All rights reserved. Forward-Looking Statements This presentation contains forward-looking statements ? 2022 Axcella Therapeutics. All rights reserved. NASDAQ: AXLA Axcella Therapeutics Investor Presentation January 2022 ? 2022 Axcella Therapeutics. All rights reserved. Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding the charac
January 10, 2022	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2022 AXCELLA HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-38901 26-3321056 (State or other jurisdiction of incorporation) (Commission Fi
December 7, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2021 AXCELLA HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-38901 26-3321056 (State or other jurisdiction of incorporation) (Commission Fi
December 7, 2021	EX-99.1	Axcella Therapeutics Promotes Margaret Koziel, M.D., to Chief Medical Officer Exhibit 99.1 Axcella Therapeutics Promotes Margaret Koziel, M.D., to Chief Medical Officer Cambridge, Mass., December 6, 2021 ? Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that Margaret Koziel, M.D., has been promoted to the rol
December 7, 2021	EX-10.1	Employment Agreement, by and between the Company and Margaret Koziel, dated as of December 1, 2021. Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (?Agreement?) is made as of the 1st Day of December, 2021 between Axcella Health Inc. d/b/a Axcella Therapeutics, a Delaware corporation (the ?Company?), and Margaret Koziel, MD (the ?Executive?). WHEREAS, the Company and the Executive are parties to an Employment Agreement dated as of August 31, 2020 (the ?Prior Agreement?); WHEREAS, the
November 10, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2021 AXCELLA HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-38901 26-3321056 (State or other jurisdiction of incorporation) (Commission F
November 10, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ______________________________________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-38501
November 10, 2021	EX-99.1	Axcella Therapeutics Reports Third Quarter Financial Results and Provides Update on Long COVID, OHE and NASH Clinical Trials Exhibit 99.1 Axcella Therapeutics Reports Third Quarter Financial Results and Provides Update on Long COVID, OHE and NASH Clinical Trials Cambridge, Mass., November 10, 2021 ? Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced financia
September 7, 2021	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 2, 2021 AXCELLA HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-38901 26-3321056 (State or other jurisdiction of incorporation) (Commission F
September 7, 2021	EX-10.1	Loan and Security Agreement, dated September 2, 2021, by and between Axcella Health Inc. and SLR Investment Corp. Exhibit 10.1 Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark ?[***]?. LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT (as the same may be amended, restated, modif
July 29, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ______________________________________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-38501 AXCE
July 29, 2021	EX-10.1	Employment Agreement between the Registrant and Virginia Dean, dated June 9, 2021. Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is made as of the 9th Day of June, 2021 between Axcella Health Inc., a Delaware corporation (the “Company”), and Virginia R. Dean (the “Executive”). WHEREAS, the Company desires to employ the Executive and the Executive desires to be employed by the Company on the terms and conditions contained herein commencing on June 21,
July 29, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2021 AXCELLA HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-38901 26-3321056 (State or other jurisdiction of incorporation) (Commission File
July 29, 2021	EX-99.1	Axcella Reports Second Quarter Financial Results and Provides Business Update Exhibit 99.1 Axcella Reports Second Quarter Financial Results and Provides Business Update ?Initiated EMMPOWER Phase 2 clinical trial of AXA1665 for the reduction in risk of recurrent OHE ?Initiated EMMPACT Phase 2b clinical trial of AXA1125 for the treatment of NASH ?Presented data at key medical congresses ?Enhanced management team with the addition of Chief People Officer ?Company to host confe
May 21, 2021	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2021 AXCELLA HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-38901 26-3321056 (State or other jurisdiction of incorporation) (Commission File N
May 6, 2021	10-Q	Quarterly Report - 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-38501 AXC
May 6, 2021	EX-99.1	Axcella Reports First Quarter Financial Results and Provides Business Update Exhibit 99.1 Axcella Reports First Quarter Financial Results and Provides Business Update ?AXA1665 IND application cleared by FDA for the reduction in risk of recurrent OHE ?AXA1125 IND application cleared by FDA for the treatment of NASH ?Initiation of AXA1665 Phase 2 and AXA1125 Phase 2b clinical trials expected shortly ?Company to host conference call at 8:30 a.m. ET today Cambridge, Mass., May
May 6, 2021	EX-99.2	© 2021 Axcella Health Inc. All rights reserved. NASDAQ: AXLA Capitalizing on an Accelerated Path to Late-Stage Development May 2021 © 2021 Axcella Health Inc. All rights reserved. 2 Forward-Looking Statements This presentation contains forward-lookin ? 2021 Axcella Health Inc. All rights reserved. NASDAQ: AXLA Capitalizing on an Accelerated Path to Late-Stage Development May 2021 ? 2021 Axcella Health Inc. All rights reserved. 2 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regardi
May 6, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2021 AXCELLA HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-38901 26-3321056 (State or other jurisdiction of incorporation) (Commission File Nu
April 5, 2021	DEFA14A	- DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin
April 5, 2021	DEF 14A	- DEF 14A TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.??) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitted by Rule
March 17, 2021	EX-99.1	Axcella Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update Exhibit 99.1 Axcella Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update ?First IND application cleared by FDA for AXA1665 ?Initiation of AXA1665 Phase 2 clinical trial in OHE expected in Q2 2021 ?Initiation of AXA1125 Phase 2b clinical trial in NASH expected in Q2 2021 ?Company to host conference call at 8:30 a.m. ET today Cambridge, Mass., March 17, 2021 ? Ax
March 17, 2021	10-K	Annual Report - 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-38501 AXCELLA
March 17, 2021	EX-21.1	Subsidiaries of the Registrant Exhibit 21.1 List of Subsidiaries Subsidiary Jurisdiction of incorporation or organization Acora Nutrition LLC Delaware Axcella Health Securities Corporation Massachusetts
March 17, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2021 AXCELLA HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-38901 26-3321056 (State or other jurisdiction of incorporation) (Commission File
March 17, 2021	EX-10.18	Lease Extension and Modification Agreement to the Lease Agreement between Rivertech Associates II, LLC and the Registrant, dated as of Exhibit 10.18 RIVERSIDE TECHNOLOGY CENTER SIXTH LEASE EXTENSION AND MODIFICATION AGREEMENT TO THE LEASE BETWEEN RIVERTECH ASSOCIATES II LLC AND AXCELLA HEALTH, INC., (f/k/a PRONUTRIA BIOSCIENCES, INC. and f/k/a ESSENTIENT, INC.) This Sixth Lease Extension and Modification Agreement (the "Sixth Lease Amendment") entered into this 1st day of October, 2020 by and between Rivertech Associates II, LLC,
March 3, 2021	EX-99.1	Axcella Announces Alison D. Schecter, M.D., as President of R&D Experienced biopharma leader to oversee research, candidate development, clinical and regulatory functions Exhibit 99.1 Axcella Announces Alison D. Schecter, M.D., as President of R&D Experienced biopharma leader to oversee research, candidate development, clinical and regulatory functions Cambridge, Mass., MARCH 3, 2021 ? Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compo
March 3, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2021 AXCELLA HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-38901 26-3321056 (State or other jurisdiction of incorporation) (Commission File
March 3, 2021	EX-10.1	, 2021 (incorporated by reference to Exhibit 10.1 to Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (?Agreement?) is made as of the 2nd Day of March, 2021 between Axcella Health Inc., a Delaware corporation (the ?Company?), and Alison Schecter (the ?Executive?). WHEREAS, the Company desires to employ the Executive and the Executive desires to be employed by the Company on the terms and conditions contained herein commencing on March 15,
February 16, 2021	SC 13G/A	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Axcella Health Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) (CUSIP Nu SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Axcella Health Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 05454B105 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pur
February 12, 2021	EX-99.1	JOINT FILING AGREEMENT EX-99.1 2 d129040dex991.htm EX-99.1 EXHIBIT I JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersign
February 12, 2021	SC 13G/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3) Axcella Health Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) (CUSIP SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3) Axcella Health Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 05454B105 (CUSIP Number) Nestlé S.A. Avenue Nestlé, 55 1800 Vevey Switzerland Attention: General Counsel Facsimile: 011-41-21-924-2821 with a copy
November 12, 2020	EX-99.1	Axcella Reports Third Quarter 2020 Financial Results and Provides Business Update Exhibit 99.1 Axcella Reports Third Quarter 2020 Financial Results and Provides Business Update •Plan to advance AXA1125 directly into a Phase 2b biopsy clinical trial in NASH under IND following successful Type B pre-IND meeting with FDA •Plan to advance AXA1665 directly into a Phase 2 clinical trial in OHE under IND following positive top-line data from AXA1665-002 •Published peer-reviewed manusc
November 12, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2020 AXCELLA HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-38901 26-3321056 (State or other jurisdiction of incorporation) (Commission F
November 12, 2020	EX-10.1	First Amendment to Amended and Restated Employment Agreement between the Registrant and Manu Chakravarthy, dated August 1, 2020 (incorporated by reference to Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 12, 2020). Exhibit 10.1 FIRST AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT This First Amendment to Amended and Restated Employment Agreement (this “Amendment”) is made effective as of August 1, 2020 (the “Amendment Effective Date”), by and between Axcella Health Inc., a Delaware corporation (the “Company”), and Manu Chakravarthy, M.D., Ph.D. (the “Executive”). WHEREAS, the Company and the Executive
November 12, 2020	EX-10.2	First Amendment to Amended and Restated Employment Agreement between the Registrant and Paul Fehlner, dated September 16, 2020 Exhibit 10.2 FIRST AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT This First Amendment to Amended and Restated Employment Agreement (this “Amendment”) is made effective as of September 16, 2020 (the “Amendment Effective Date”), by and between Axcella Health Inc., a Delaware corporation (the “Company”), and Paul Fehlner, J..D., Ph.D. (the “Executive”). WHEREAS, the Company and the Executive
November 12, 2020	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-38501
September 10, 2020	SC 13G/A	AXLA / Axcella Health Inc. / Nestle Health Science US Holdings, Inc. - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) Axcella Health Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 05454B105 (CUSIP Number) Nestlé S.A. Avenue Nestlé, 55 1800 Vevey Switzerland Attention: General Counsel Facsimile: 011-41-21-924-2821 with a copy
September 10, 2020	EX-99.(I)	JOINT FILING AGREEMENT EX-99.(I) EXHIBIT I JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each s
August 31, 2020	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 28, 2020 AXCELLA HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-38901 26-3321056 (State or other jurisdiction of incorporation) (Commission Fil
August 31, 2020	EX-10.1	Third Amendment to Loan and Security Agreement, dated August 28, 2020, between the Registrant and Solar Capital Ltd. (Incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K (File No. 001-38901) filed with the Securities and Exchange Commission on August 31, 2020). Exhibit 10.1 THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”), dated as of August 28, 2020 (the “Amendment Effective Date”), is made among Axcella Health Inc., a Delaware corporation (the “Axcella”), and Acora Nutrition LLC, a Delaware limited liability company (“Acora” and, individually and collectively, jointly and severally wi
August 5, 2020	EX-99.2	NASDAQ: AXLA AXA1665-002 Top-Line Data August 5, 2020 © 2020 Axcella Health Inc. All rights reserved. Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act axa1665-002toplinedatain NASDAQ: AXLA AXA1665-002 Top-Line Data August 5, 2020 © 2020 Axcella Health Inc.
August 5, 2020	EX-99.1	Axcella Reports Positive Top-Line Data from AXA1665-002 and Second Quarter Financial Results Exhibit 99.1 Axcella Reports Positive Top-Line Data from AXA1665-002 and Second Quarter Financial Results •Top-line data from AXA1665-002 show dose dependent improvements in markers of cognitive function and amino acid metabolism; both AXA1665 doses safe and well tolerated for 12 Weeks; plan to initiate Phase 2 clinical trial under IND in 1H 2021 •Reported positive top-line data for AXA1125, Axcel
August 5, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2020 AXCELLA HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-38901 26-3321056 (State or other jurisdiction of incorporation) (Commission File
August 5, 2020	EX-10.1	Employment Agreement between the Registrant and Andrew Suchoff, dated June 18, 2020 (incorporated by reference to Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 5, 2020). EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is made as of the 18th of June, 2020 between Axcella Health Inc.
August 5, 2020	10-Q	Quarterly Report - 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-38501 AXCE
June 12, 2020	424B5	Up to $35,000,000 Common Stock TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-238983 PROSPECTUS Up to $35,000,000 Common Stock We have entered into a sales agreement, or the Sales Agreement, with SVB Leerink LLC, or SVB Leerink, relating to shares of our common stock offered by this prospectus. In accordance with the terms of the Sales Agreement, we may offer and sell shares of our common stock having
June 10, 2020	CORRESP	- June 10, 2020 Via EDGAR Transmission United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.
June 5, 2020	EX-4.3	Form of Senior Indenture between Registrant and one or more trustees to be named Exhibit 4.3 AXCELLA HEALTH INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [●] Senior Debt Securities TABLE OF CONTENTS1 ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee’s Certificate 6 Section
June 5, 2020	EX-4.4	Form of Subordinated Indenture between Registrant and one or more trustees to be named Exhibit 4.4 AXCELLA HEALTH INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [●] Subordinated Debt Securities TABLE OF CONTENTS1 ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee’s Certificate 6 Sec
June 5, 2020	EX-1.2	Sales Agreement, dated as of June 5, 2020, between the Registrant and SVB Leerink LLC Exhibit 1.2 Axcella Health Inc. Shares of Common Stock ($0.001 par value per share) SALES AGREEMENT June 5, 2020 SVB LEERINK LLC 1301 Avenue of the Americas, 12th Floor New York, New York 10019 Ladies and Gentlemen: Axcella Health Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with SVB Leerink LLC (the “Agent”), as follows: 1. Issuance and Sale of Shares. T
June 5, 2020	S-3	- FORM S-3 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on June 5, 2020.
June 5, 2020	S-8	- FORM S-8 As filed with the Securities and Exchange Commission on June 5, 2020 Registration No.
May 21, 2020	EX-99.(I)	JOINT FILING AGREEMENT EX-99.(I) EXHIBIT I JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each s
May 21, 2020	SC 13G	AXLA / Axcella Health Inc. / Nestle Health Science US Holdings, Inc. - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Axcella Health Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 05454B105 (CUSIP Number) Nestlé S.A. Avenue Nestlé, 55 1800 Vevey Switzerland Attention: General Counsel Facsimile: 011-41-21-924-2821 with a copy to: David A. Carpent
May 20, 2020	SC 13D	AXLA / Axcella Health Inc. / Flagship Venturelabs Iv, Llc - SC 13D Activist Investment SC 13D SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* AXCELLA HEALTH INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 05454B105 (CUSIP Number) Noubar B. Afeyan, Ph.D. Flagship Pioneering 55 Cambridge Parkway, Suite 800E Cambridge, MA 02142 (617) 868-1888 (Name, Address
May 20, 2020	EX-99.1	JOINT FILING AGREEMENT EX-99.1 Exhibit 99.1 CUSIP No. 05454B105 JOINT FILING AGREEMENT The persons below hereby agree that the Schedule 13D to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13D, shall be filed jointly on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Date
May 20, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2020 AXCELLA HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-38901 26-3321056 (State or other jurisdiction of incorporation) (Commission File N
May 18, 2020	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2020 AXCELLA HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-38901 26-3321056 (State or other jurisdiction of incorporation) (Commission File N
May 18, 2020	EX-99.2	Axcella Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option Exhibit 99.2 Axcella Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option CAMBRIDGE, Mass. – May 18, 2020 – Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators (EMMs) to pioneer a new approach for treating complex diseases and improving health, today announced the closing of its underw
May 18, 2020	EX-99.1	Axcella Announces Pricing of Public Offering of Common Stock Exhibit 99.1 Axcella Announces Pricing of Public Offering of Common Stock CAMBRIDGE, Mass. – May 13, 2020 – Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators (EMMs) to pioneer a new approach for treating complex diseases and improving health, today announced the pricing of its underwritten public offering of 11,000,000 shares of it
May 14, 2020	424B4	11,000,000 Shares Axcella Health Inc. Common Stock Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. 333-238168 PROSPECTUS 11,000,000 Shares Axcella Health Inc. Common Stock We are offering 11,000,000 shares of our common stock. Our common stock is listed on the Nasdaq Global Market under the symbol "AXLA." On May 13, 2020, the last reported sale price of our common stock as reported on the Nasdaq Global Market was $5.34 per shar
May 11, 2020	EX-1.1	Form of Underwriting Agreement Exhibit 1.1 AXCELLA HEALTH INC. [ · ] Shares of Common Stock Underwriting Agreement [ · ], 2020 J.P. Morgan Securities LLC SVB Leerink LLC As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o SVB Leerink LLC 1301 Avenue of the Americas, 12th Floor New York, New York 10019 Ladies and Gentlemen: Axce
May 11, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2020 AXCELLA HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-38901 26-3321056 (State or other jurisdiction of incorporation) (Commission File N
May 11, 2020	EX-99.1	Axcella Reports First Quarter Financial Results and Provides Business Update Exhibit 99.1 Axcella Reports First Quarter Financial Results and Provides Business Update •Reported positive top-line data from AXA1125-003, with clinically relevant reductions in liver fat content, insulin resistance and fibroinflammation observed in subjects with NAFLD receiving AXA1125 •Completed enrollment of AXA1665-002, with data readout expected in Q3 2020 •Announced AXA2678 patent issuance
May 11, 2020	CORRESP	- VIA EDGAR May 11, 2020 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Paul Fischer Re: Axcella Health Inc. Acceleration Request for Registration Statement on Form S-1 File No. 333-238168 Requested Date: May 13, 2020 Requested Time: 4:00 p.m. Eastern Standard Time Dear Mr. Fischer: Pursuant to Rule 461 under the Securities Act
May 11, 2020	10-Q	Quarterly Report - 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-38501 AXC
May 11, 2020	EX-10.1	Amended and Restated Employment Agreement between the Registrant and Manu Chakravarthy, dated December 29, 2018 (incorporated by reference to Exhibit 10.1 to the Registrant's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 11, 2020). EXHIBIT 10.1 Amended and Restated employment AGREEMENT This Amended and Restated Employment Agreement (“Agreement”) is made as of the 29th day of December, 2018 (the “Effective Date”), between Axcella Health Inc. a Delaware corporation (the “Company”), and Manu Chakravarthy, M.D., Ph.D. (the “Executive”). Except with respect to the Restrictive Covenants Agreement and the Equity Documents (each as
May 11, 2020	EX-3.2	2 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-38901) filed with the Securities and Exchange Commission on May 11, 2020). AMENDED AND RESTATED BY-LAWS OF AXCELLA HEALTH INC. (the “Corporation”) ARTICLE I Stockholders SECTION 1. Annual Meeting. The annual meeting of stockholders (any such meeting being referred to in these By-laws as an “Annual Meeting”) shall be held at the hour, date and place within or without the United States which is fixed by the Board of Directors, which time, date and place may subsequently be
May 11, 2020	S-1	Registration Statement - S-1 Table of Contents As filed with the Securities and Exchange Commission on May 11, 2020.
May 11, 2020	CORRESP	- VIA EDGAR May 11, 2020 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Paul Fischer Re: Axcella Health Inc. Acceleration Request for Registration Statement on Form S-1 File No. 333-238168 Requested Date: May 13, 2020 Requested Time: 4:00 p.m. Eastern Standard Time Dear Mr. Fischer: In accordance with Rule 461 under the Securit
May 8, 2020	EX-3.1	Amendment to the Amended and Restated Bylaws of Registrant (Incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-38901) filed with the Securities and Exchange Commission on May 8, 2020). Exhibit 3.1 AMENDMENT TO THE AMENDED AND RESTATED BY-LAWS Section 8 of Article VI of the Amended and Restated By-laws of Axcella Health Inc. is hereby amended and restated in its entirety to read as follows: “SECTION 8. Exclusive Jurisdiction. Unless the Corporation consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware shall be the sole and ex
May 8, 2020	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2020 AXCELLA HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-38901 26-3321056 (State or other jurisdiction of incorporation) (Commission File Nu
May 6, 2020	EX-99.2	© 2020 Axcella Health Inc. All rights reserved. NASDAQ: AXLA AXA1125 - 003 Top - Line Data May 6, 2020 Exhibit 99.2 © 2020 Axcella Health Inc. All rights reserved. NASDAQ: AXLA AXA1125 - 003 Top - Line Data May 6, 2020 © 2020 Axcella Health Inc. All rights reserved. 2 This presentation contains forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 , as amended, including, without limitation, statements regarding the characteristics, competitive posi
May 6, 2020	EX-99.1	Axcella Announces Positive Top-Line Data from AXA1125-003 Clinical Study Showing Multifactorial Activity in Adult Subjects with NAFLD Exhibit 99.1 Axcella Announces Positive Top-Line Data from AXA1125-003 Clinical Study Showing Multifactorial Activity in Adult Subjects with NAFLD • Clinically relevant reductions in liver fat content, insulin resistance and fibroinflammation markers observed with AXA1125 along with favorable tolerability, supporting its potential to be a first-line NASH therapy • Greater activity in key markers s
May 6, 2020	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2020 AXCELLA HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-38901 26-3321056 (State or other jurisdiction of incorporation) (Commission File Nu
May 4, 2020	DEFA14A	- DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin
April 3, 2020	DEF 14A	definitive proxy statement on Schedule 14A (other than information furnished rather than filed), which was filed with the SEC on April 3, 2020; Use these links to rapidly review the document Table of Contents Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
April 3, 2020	DEFA14A	AXLA / Axcella Health Inc. DEFA14A - - DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin
April 3, 2020	DRS	- Table of Contents As confidentially submitted to the Securities and Exchange Commission on April 3, 2020.
March 23, 2020	EX-99.1	Axcella Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update Exhibit 99.1 Axcella Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update •Announced positive interim findings from ongoing clinical study of AXA1125 and AXA1957; expect to report top-line data in second quarter of 2020 •Completed enrollment in ongoing clinical study of AXA1665; expect to report top-line data in third quarter of 2020 •Bolstered intellectual prop
March 23, 2020	10-K	Annual Report - 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-38501 AXCELLA
March 23, 2020	EX-21.1	Subsidiaries of the Registrant Exhibit 21.1 List of Subsidiaries Subsidiary Jurisdiction of incorporation or organization Acora Nutrition LLC Delaware Axcella Health Securities Corporation Massachusetts
March 23, 2020	EX-4.3	Description of the Registrant’s Securities Exhibit 4.3 Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 The summary of the general terms and provisions of the registered securities of Axcella Health Inc. (the “Company,” “we,” “us,” and “our”) set forth below does not purport to be complete. It is subject to and qualified in its entirety by reference to our Restated Certific
March 23, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2020 AXCELLA HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-38901 26-3321056 (State or other jurisdiction of incorporation) (Commission File
February 13, 2020	SC 13G	AXLA / Axcella Health Inc. / Nestle Health Science US Holdings, Inc. - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Axcella Health Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 05454B105 (CUSIP Number) Nestlé S.A. Avenue Nestlé, 55 1800 Vevey Switzerland Attention: General Counsel Facsimile: 011-41-21-924-2821 with a copy to: David A. Carpent
February 7, 2020	SC 13G	AXLA / Axcella Health Inc. / Gurnet Point L.P. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 AXCELLA HEALTH INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 05454B105 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which
February 5, 2020	EX-99.1	AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13G EX-99.1 Exhibit 99.1 AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13G Pursuant to Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned agree that the Statement on Schedule 13G to which this Exhibit is attached is filed on behalf of each of them. Each of them is individually eligible to use the Schedule 13G to which this Exhibit is attached. Each o
February 5, 2020	SC 13G	AXLA / Axcella Health Inc. / Harbourvest Partners L.p. - SC 13G Passive Investment SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Axcella Health Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 05454B105 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua
November 25, 2019	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 25, 2019 AXCELLA HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-38901 26-3321056 (State or other jurisdiction of incorporation) (Commission F
November 25, 2019	EX-10.1	Employment Agreement between the Registrant and Laurent Chardonnet, dated November 11, 2019. (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K (File No. 001-38901) filed with the Securities and Exchange Commission on November 25, 2019). EXHIBIT 10.1 employment AGREEMENT This Employment Agreement (“Agreement”) is made as of the 11th of November, 2019 between Axcella Health Inc., a Delaware corporation (the “Company”), and Laurent Chardonnet (the “Executive”). WHEREAS, the Company desires to employ the Executive and the Executive desires to be employed by the Company on the terms and conditions contained herein commencing on Decemb
November 25, 2019	EX-99.1	Axcella Strengthens Executive Team with Key Addition and Promotion EXHIBIT 99.1 Axcella Strengthens Executive Team with Key Addition and Promotion · Appoints Laurent Chardonnet as Chief Financial Officer · Promotes Heidy King-Jones to General Counsel CAMBRIDGE, Mass. – November 25, 2019 – Axcella Health (Nasdaq: AXLA), a biotechnology company pioneering the research and development of novel multifactorial interventions to address dysregulated metabolism and suppo
November 12, 2019	10-Q	Quarterly Report - 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-38501
November 12, 2019	EX-10.2	Chairman and Consulting Agreement between the Registrant and the Chairman of the Board of Directors, dated August 22, 2019 (incorporated by reference to Exhibit 10.2 to the Registrant’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 12, 2019). Chairman and Consulting Agreement This agreement (the “Agreement”), effective August 22, 2019 (the “Effective Date”), between David Epstein, and Axcella Health Inc.
November 12, 2019	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2019 AXCELLA HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-38901 26-3321056 (State or other jurisdiction of incorporation) (Commission F
November 12, 2019	EX-10.1	Separation Agreement between the Registrant and Thomas Leggett, dated August 22, 2019. August 22, 2019 Thomas Leggett [*] [*] Re: Separation Agreement Dear Thomas: The purpose of this letter agreement (the “Agreement”) is to confirm the terms regarding your separation of employment from Axcella Health Inc.
November 8, 2019	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2019 AXCELLA HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-38901 26-3321056 (State or other jurisdiction (Commission (IRS Employer of inc
August 23, 2019	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 23, 2019 AXCELLA HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-38901 26-3321056 (State or other jurisdiction of incorporation) (Commission Fil
August 12, 2019	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2019 AXCELLA HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-38901 26-3321056 (State or other jurisdiction of incorporation) (Commission Fil
August 12, 2019	10-Q	Quarterly Report - 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED June 30, 2019 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-38501 AXCE
August 12, 2019	EX-10.1	Employment Agreement between the Registrant and Shreeram Aradhye, dated January 1, 2019 (incorporated by reference to Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 12, 2019). EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is made as of the 1stth of January, 2019 (the “Effective Date”), between Axcella Health Inc.
June 20, 2019	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2019 AXCELLA HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-38901 26-3321056 (State or other jurisdiction of incorporation) (Commission File
June 20, 2019	10-Q	AXLA / Axcella Health Inc. 10-Q - Quarterly Report - 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED March 31, 2019 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-38501 AXC
May 23, 2019	SC 13D	AXLA / Axcella Health Inc. / Flagship Venturelabs Iv, Llc - SC 13D Activist Investment SC 13D SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* AXCELLA HEALTH INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 05454B105 (CUSIP Number) Noubar B. Afeyan, Ph.D. Flagship Pioneering 55 Cambridge Parkway, Suite 800E Cambridge, MA 02142 (617) 868-1888 (Name, Address a
May 23, 2019	EX-99.1	JOINT FILING AGREEMENT EX-99.1 CUSIP No. 05454B105 Exhibit 99.1 JOINT FILING AGREEMENT The persons below hereby agree that the Schedule 13D to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13D, shall be filed jointly on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Date
May 17, 2019	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2019 Axcella Health Inc. (Exact name of registrant as specified in its charter) Delaware 001-38901 26-3321056 (State or other jurisdiction of incorporation) (Commission File N
May 17, 2019	EX-3.4	Amended and Restated Bylaws of Registrant (Incorporated by reference to Exhibit 3.4 to the Registrant’s Current Report on Form 8-K (File No. 001-38901) filed with the Securities and Exchange Commission on May 13, 2019). Exhibit 3.4 AMENDED AND RESTATED BY-LAWS OF AXCELLA HEALTH INC. (the “Corporation”) ARTICLE I Stockholders SECTION 1. Annual Meeting. The annual meeting of stockholders (any such meeting being referred to in these By-laws as an “Annual Meeting”) shall be held at the hour, date and place within or without the United States which is fixed by the Board of Directors, which time, date and place may sub
May 17, 2019	EX-3.1	Amended and Restated Certificate of Incorporation of Axcella Health Inc. Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF AXCELLA HEALTH INC. Axcella Health Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as follows: 1. The name of the Corporation is Axcella Health Inc. The date of the filing of its original Certificate of Incorporation with the Secretary of State of the State of D
May 17, 2019	EX-3.3	Restated Certificate of Incorporation of the Registrant (Incorporated by reference to Exhibit 3.3 to the Registrant’s Current Report on Form 8-K (File No. 001-38901) filed with the Securities and Exchange Commission on May 13, 2019). Exhibit 3.3 RESTATED CERTIFICATE OF INCORPORATION OF AXCELLA HEALTH INC. Axcella Health Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as follows: 1. The name of the Corporation is Axcella Health Inc. The date of the filing of its original Certificate of Incorporation with the Secretary of State of the State of Delaware was
May 17, 2019	EX-3.2	Certificate of Retirement of Convertible Preferred Stock of Axcella Health Inc. Exhibit 3.2 CERTIFICATE OF RETIREMENT OF SERIES B CONVERTIBLE PREFERRED STOCK SERIES B-1 CONVERTIBLE PREFERRED STOCK SERIES C CONVERTIBLE PREFERRED STOCK SERIES D CONVERTIBLE PREFERRED STOCK AND SERIES E CONVERTIBLE PREFERRED STOCK OF AXCELLA HEALTH INC. Pursuant to Section 243(b) of the General Corporation Law of the State of Delaware Axcella Health Inc., a corporation organized and existing unde
May 17, 2019	S-8	Form S-8 (Registration No. 333-231570) on May 17, 2019 As filed with the Securities and Exchange Commission on May 17, 2019 Registration No.
May 9, 2019	424B4	3,571,428 Shares Axcella Health Inc. Common Stock Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS 2 Table of Contents Filed Pursuant to Rule 424(6)(4) Registration No.
May 7, 2019	8-A12B	the description of our common stock contained in our registration statement on Form 8-A filed with the SEC on May 7, 2019, including any amendments or reports filed for the purposes of updating this description. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Axcella Health Inc.
May 6, 2019	CORRESP	AXLA / Axcella Health Inc. CORRESP - - VIA EDGAR May 6, 2019 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: David Plattner Tom Kluck Re: Axcella Health Inc. Acceleration Request for Registration Statement on Form S-1 File No. 333-230822 Requested Date: May 8, 2019 Requested Time: 4:00 p.m. Eastern Standard Time Dear Mr. Plattner and Mr. Kluck: Pursuant to Rule 461
May 6, 2019	S-1/A	As filed with the Securities and Exchange Commission on May 6, 2019. Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS 2 Table of Contents As filed with the Securities and Exchange Commission on May 6, 2019.
May 6, 2019	EX-10.6	Amended and Restated Employment Agreement between the Registrant and Thomas Leggett, dated December 31, 2018 Exhibit 10.6 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (?Agreement?) is made as of the 31st day of December, 2018 (the ?Effective Date?), between Axcella Health Inc. a Delaware corporation (the ?Company?), and Thomas Leggett (the ?Executive?). Except with respect to the Restrictive Covenants Agreement and the Equity Documents (each as defined below),
May 6, 2019	CORRESP	AXLA / Axcella Health Inc. CORRESP - - VIA EDGAR May 6, 2019 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: David Plattner Tom Kluck Re: Axcella Health Inc. Acceleration Request for Registration Statement on Form S-1 File No. 333-230822 Requested Date: May 8, 2019 Requested Time: 4:00 p.m. Eastern Standard Time Dear Mr. Plattner and Mr. Kluck: In accordance with R
May 6, 2019	EX-10.7	Amended and Restated Employment Agreement between the Registrant and Stephen Mitchener, dated December 29, 2018 (incorporated by reference to Exhibit 10.7 to the Registrant’s Amendment No. 2 to the Registration Statement on Form S-1 (File No. 333-230822) filed with the Securities and Exchange Commission on May 6, 2019). Exhibit 10.7 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (?Agreement?) is made as of the 29th day of December, 2018 (the ?Effective Date?), between Axcella Health Inc. a Delaware corporation (the ?Company?), and Stephen Mitchener (the ?Executive?). Except with respect to the Restrictive Covenants Agreement and the Equity Documents (each as defined below
May 6, 2019	EX-10.5	Amended and Restated Employment Agreement between the Registrant and William Hinshaw, dated December 20, 2018 (incorporated by reference to Exhibit 10.5 to the Registrant’s Amendment No. 2 to the Registration Statement on Form S-1 (File No. 333-230822) filed with the Securities and Exchange Commission on May 6, 2019). Exhibit 10.5 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (?Agreement?) is made as of the 20th day of December, 2018 (the ?Effective Date?), between Axcella Health Inc. a Delaware corporation (the ?Company?), and William R. Hinshaw, Jr. (the ?Executive?). Except with respect to the Equity Documents (as defined below), this Agreement supersedes in all res
May 6, 2019	EX-3.8	Form of Amended and Restated Bylaws (to be effective upon the completion of this offering) Exhibit 3.8 AMENDED AND RESTATED BY-LAWS OF AXCELLA HEALTH INC. (the ?Corporation?) ARTICLE I Stockholders SECTION 1. Annual Meeting. The annual meeting of stockholders (any such meeting being referred to in these By-laws as an ?Annual Meeting?) shall be held at the hour, date and place within or without the United States which is fixed by the Board of Directors, which time, date and place may sub
May 6, 2019	CORRESP	AXLA / Axcella Health Inc. CORRESP - - Goodwin Procter LLP 100 Northern Avenue Boston, MA 02210 goodwinlaw.com +1 617 570 1000 May 6, 2019 VIA EDGAR AND FEDERAL EXPRESS Mr. David Plattner Mr. Tom Kluck Office of Healthcare and Insurance Division of Corporation Finance Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Axcella Health Inc. Amendment No. 1 to Registration Statement on Form S-1 Filed April 30,
May 6, 2019	EX-10.2	2019 Stock Option and Incentive Plan and forms of award agreements thereunder (incorporated by reference to Exhibit 10.2 to the Registrant’s Amendment No. 2 to the Registration Statement on Form S-1 (File No. 333-230822) filed with the Securities and Exchange Commission on May 6, 2019). Exhibit 10.2 AXCELLA HEALTH INC. 2019 STOCK OPTION AND INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Axcella Health Inc. 2019 Stock Option and Incentive Plan (the ?Plan?). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consultants of Axcella Health Inc. (the ?Company?) and its Affiliates upon w
April 30, 2019	S-1/A	Specimen Stock Certificate evidencing shares of common stock (Incorporated by reference to Exhibit 4.1 to the Registrant’s Amendment No. 1 to the Registration Statement on Form S-1/A (File No. 333-230822) filed with the Securities and Exchange Commission on April 30, 2019). Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS 2 Table of Contents As filed with the Securities and Exchange Commission on April 30, 2019.
April 30, 2019	EX-3.6	Form of Restated Certificate of Incorporation of the Registrant (to be effective upon the completion of this offering) Exhibit 3.6 RESTATED CERTIFICATE OF INCORPORATION OF AXCELLA HEALTH INC. Axcella Health Inc., a corporation organized and existing under the laws of the State of Delaware (the ?Corporation?), hereby certifies as follows: 1. The name of the Corporation is Axcella Health Inc. The date of the filing of its original Certificate of Incorporation with the Secretary of State of the State of Delaware was
April 30, 2019	EX-10.1	2010 Stock Incentive Plan, as amended (incorporated by reference to Exhibit 10.1 to the Registrant’s Amendment No. 1 to the Registration Statement on Form S-1 (File No. 333-230822) filed with the Securities and Exchange Commission on April 30, 2019). EX-10.1 11 a2238646zex-101.htm EX-10.1 Exhibit 10.1 ESSENTIENT, INC. 2010 STOCK OPTION AND GRANT PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Essentient, Inc. 2010 Stock Option and Grant Plan (the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, directors, Consultants and other key persons (including prospective employees,
April 30, 2019	EX-10.13	First Amendment to Loan and Security Agreement, dated October 5, 2018 Exhibit 10.13 FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT (this ?Amendment?), dated as of October 5, 2018 (the ?Amendment Effective Date?), is made among Axcella Health Inc., a Delaware corporation (the ?Axcella?), and Acora Nutrition LLC, a Delaware limited liability company (?Acora? and, individually and collectively, jointly and severally w
April 30, 2019	EX-3.4	Form of Amended and Restated Certificate of Incorporation of the Registrant (to be effective immediately prior to the completion of this offering) Exhibit 3.4 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF AXCELLA HEALTH INC. Axcella Health Inc., a corporation organized and existing under the laws of the State of Delaware (the ?Corporation?), hereby certifies as follows: 1. The name of the Corporation is Axcella Health Inc. The date of the filing of its original Certificate of Incorporation with the Secretary of State of the State of D
April 30, 2019	EX-10.4	Senior Executive Cash Incentive Bonus Plan (incorporated by reference to Exhibit 10.4 to the Registrant’s Amendment No. 1 to the Registration Statement on Form S-1 (File No. 333-230822) filed with the Securities and Exchange Commission on April 30, 2019). Exhibit 10.4 AXCELLA HEALTH INC. SENIOR EXECUTIVE CASH INCENTIVE BONUS PLAN 1. Purpose This Senior Executive Cash Incentive Bonus Plan (the ?Incentive Plan?) is intended to provide an incentive for superior work and to motivate eligible executives of Axcella Health Inc. (the ?Company?) and its subsidiaries toward even higher achievement and business results, to tie their goals and interests to tho
April 30, 2019	EX-10.12	Loan and Security Agreement among Solar Capital Ltd. and the Lenders thereto and the Registrant, dated as of January 9, 2018 (incorporated by reference to Exhibit 10.12 to the Registrant’s Amendment No. 1 to the Registration Statement on Form S-1 (File No. 333-230822) filed with the Securities and Exchange Commission on April 30, 2019). Exhibit 10.12 SOLAR CAPITAL LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT (as the same may be amended, restated, modified, or supplemented from time to time, this ?Agreement?) dated as of January 9, 2018 (the ?Effective Date?) among SOLAR CAPITAL LTD., a Maryland corporation, with an office located at 500 Park Avenue, 3rd Floor, New York, NY 10022 (?SolarCap?), as collateral agent (
April 30, 2019	EX-10.2	2019 Stock Option and Incentive Plan and forms of award agreements thereunder Exhibit 10.2 AXCELLA HEALTH INC. 2019 STOCK OPTION AND INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Axcella Health Inc. 2019 Stock Option and Incentive Plan (the ?Plan?). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consultants of Axcella Health Inc. (the ?Company?) and its Affiliates upon w
April 30, 2019	EX-4.1	Specimen Stock Certificate evidencing shares of common stock (Incorporated by reference to Exhibit 4.1 to the Registrant’s Registration Statement on Form S-1/A (File No. 333-230822) filed with the Securities and Exchange Commission on April 30, 2019). Exhibit 4.1 ZQ\|CERT#\|COY\|CLS\|RGSTRY\|ACCT#\|TRANSTYPE\|RUN#\|TRANS# . COMMON STOCK PAR VALUE $0.001 COMMON STOCK Certificate Number ZQ00000000 Shares * * 000000 * * * * * * * * * * * * * * * * * * * * * 000000 * * * * * * * * * * * * * * * * * * * * * 000000 * * * * * * * * * * * * * * * * * * * * * 000000 * * * * * * * * * * * * * * * * * * * * * 000000 * * * * * * * * * * * * * * AXCELLA HEALTH INCO
April 30, 2019	EX-1.1	Form of Underwriting Agreement Exhibit 1.1 AXCELLA HEALTH, INC. Shares of Common Stock Underwriting Agreement , 2019 Goldman Sachs & Co. LLC J.P. Morgan Securities LLC SVB Leerink LLC As Representatives of the several Underwriters listed in Schedule 1 hereto c/o Goldman Sachs & Co. LLC 200 West Street New York, New York 10282 c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o SVB Leerink LLC 1301 Ave
April 30, 2019	EX-3.2	Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Registrant, as currently in effect Exhibit 3.2 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF AXCELLA HEALTH INC. (Pursuant to Section 242 of the General Corporation Law of the State of Delaware) Axcella Health Inc. (the ?Corporation?), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the ?DGCL?), does hereby certify that: 1. The
April 30, 2019	EX-10.16	Separation Agreement between the Registrant and Robert Connelly, effective as of May 31, 2018 Exhibit 10.16 May 7, 2018 Robert Connelly Re: Separation Agreement Dear Bob: The purpose of this letter agreement (the ?Agreement?) is to confirm the terms regarding your separation of employment from Axcella Health, Inc. (the ?Company?). As more fully set forth below, the Company desires to provide you with severance pay and benefits in exchange for certain agreements by you. This Agreement shall
April 30, 2019	EX-10.14	Second Amendment to Loan and Security Agreement, dated November 30, 2018 Exhibit 10.14 SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT (this ?Amendment?), dated as of November 30, 2018 (the ?Amendment Effective Date?), is made among Axcella Health Inc., a Delaware corporation (the ?Axcella?), and Acora Nutrition LLC, a Delaware limited liability company (?Acora? and, individually and collectively, jointly and several
April 30, 2019	EX-10.11	Fifth Lease Extension and Modification Agreement to the Lease Agreement between Rivertech Associates II, LLC and the Registrant, dated as of April 28, 2017 (incorporated by reference to Exhibit 10.11 to the Registrant’s Amendment No. 1 to the Registration Statement on Form S-1 (File No. 333-230822) filed with the Securities and Exchange Commission on April 30, 2019). Exhibit 10.11 RIVERSIDE TECHNOLOGY CENTER FIFTH LEASE EXTENSION AND MODIFICATION AGREEMENT TO THE LEASE BETWEEN RIVERTECH ASSOCIATES II LLC AND AXCELLA HEALTH, INC., (f/k/a PRONUTRIA BIOSCIENCES, INC. and f/k/a ESSENTIENT, INC.) This Fifth Lease Extension and Modification Agreement (the ?Fifth Lease Amendment?) entered into this 28th day of April, 2017 by and between Rivertech Associates II, LLC,
April 30, 2019	EX-3.5	Form of Certificate of Retirement of Convertible Preferred Stock of the Registrant (to be effective immediately prior to the completion of this offering) Exhibit 3.5 CERTIFICATE OF RETIREMENT OF SERIES B CONVERTIBLE PREFERRED STOCK SERIES B-1 CONVERTIBLE PREFERRED STOCK SERIES C CONVERTIBLE PREFERRED STOCK SERIES D CONVERTIBLE PREFERRED STOCK AND SERIES E CONVERTIBLE PREFERRED STOCK OF AXCELLA HEALTH INC. Pursuant to Section 243(b) of the General Corporation Law of the State of Delaware Axcella Health Inc., a corporation organized and existing unde
April 30, 2019	EX-3.8	Form of Amended and Restated Bylaws (Incorporated by reference to Exhibit 3.8 to the registrant’s Registration Statement on Form S-1, as amended (File No. 333-230822)). Exhibit 3.8 AMENDED AND RESTATED BY-LAWS OF AXCELLA HEALTH INC. (the ?Corporation?) ARTICLE I Stockholders SECTION 1. Annual Meeting. The annual meeting of stockholders (any such meeting being referred to in these By-laws as an ?Annual Meeting?) shall be held at the hour, date and place within or without the United States which is fixed by the Board of Directors, which time, date and place may sub
April 30, 2019	EX-10.10	Riverside Technology Center Commercial Lease Agreement between Rivertech Associates II, LLC and the Registrant, dated as of December 28, 2010 (incorporated by reference to Exhibit 10.10 to the Registrant’s Amendment No. 1 to the Registration Statement on Form S-1 (File No. 333-230822) filed with the Securities and Exchange Commission on April 30, 2019). Exhibit 10.10 INDENTURE OF LEASE by and between RIVERTECH ASSOCIATES EE, LLC (?LESSOR?) and ESSENTIENT, INC. (?LESSEE?) RIVERSIDE TECHNOLOGY CENTER 840 Memorial Drive Cambridge, Massachusetts RIVERSIDE TECHNOLOGY CENTER COMMERCIAL LEASE BETWEEN RIVERTECH ASSOCIATES H, LLC AND ESSENTBENT, INC. Agreement entered into this 28th day of December, 2010 in consideration of the covenants and other benefit
April 30, 2019	EX-3.3	Form of Amended and Restated Certificate of Incorporation of the Registrant (to be effective upon the effectiveness of the registration statement for this offering) Exhibit 3.3 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF AXCELLA HEALTH INC. Axcella Health Inc., a corporation organized and existing under the laws of the State of Delaware (the ?Corporation?), hereby certifies as follows: 1. The name of the Corporation is Axcella Health Inc. The date of the filing of its original Certificate of Incorporation with the Secretary of State of the State of D
April 30, 2019	EX-10.3	2019 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.3 to the Registrant’s Amendment No. 1 to the Registration Statement on Form S-1 (File No. 333-230822) filed with the Securities and Exchange Commission on April 30, 2019). EXHIBIT 10.3 AXCELLA HEALTH INC. 2019 EMPLOYEE STOCK PURCHASE PLAN The purpose of the Axcella Health Inc. 2019 Employee Stock Purchase Plan (?the Plan?) is to provide eligible employees of Axcella Health Inc. (the ?Company?) and each Designated Subsidiary (as defined in Section 11) with opportunities to purchase shares of the Company?s common stock, par value $0.001 per share (the ?Common Stock?).
April 24, 2019	CORRESP	AXLA / Axcella Health Inc. CORRESP - - Goodwin Procter LLP 100 Northern Avenue Boston, MA 02210 goodwinlaw.com +1 617 570 1000 CONFIDENTIAL TREATMENT REQUESTED BY AXCELLA HEALTH INC. CERTAIN PORTIONS OF THIS LETTER AS FILED VIA EDGAR HAVE BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. OMITTED INFORMATION HAS BEEN REPLACED IN THIS LETTER AS FILED VIA
April 12, 2019	EX-4.2	Fifth Amended and Restated Investors' Rights Agreement among the Registrant and certain of its stockholders, dated November 30, 2018 (Incorporated by reference to Exhibit 4.2 to the Registrant’s Registration Statement on Form S-1 (File No. 333-230822) filed with the Securities and Exchange Commission on April 12, 2019). Exhibit 4.2 AXCELLA HEALTH INC. FIFTH AMENDED AND RESTATED INVESTORS? RIGHTS AGREEMENT THIS FIFTH AMENDED AND RESTATED INVESTORS? RIGHTS AGREEMENT is made as of the 30th day of November, 2018, by and among Axcella Health Inc., a Delaware corporation (the ?Company?), and each of the investors listed on Schedule A hereto and any subsequent purchasers of Preferred Stock who become parties hereto as ?
April 12, 2019	EX-10.15	Stock Repurchase Agreement between the Registrant and Robert Connelly, effective as of May 31, 2018 Exhibit 10.15 STOCK REPURCHASE AGREEMENT THIS STOCK REPURCHASE AGREEMENT (this ?Agreement?) is effective as of the 31st day of May, 2018 (the ?Effective Date?), by and between (i) Axcella Health, Inc., a Delaware corporation (the ?Company?), and (ii) Robert Connelly (the ?Repurchase Stockholder?). RECITALS WHEREAS, the Repurchase Stockholder owns of record and beneficially 1,154,655 shares of the
April 12, 2019	EX-10.8	Form of Indemnification Agreement between the Registrant and each of its directors (incorporated by reference to Exhibit 10.8 to the Registrant’s Registration Statement on Form S-1 (File No. 333-230822) filed with the Securities and Exchange Commission on April 12, 2019). Exhibit 10.8 AXCELLA HEALTH INC. [FORM OF] DIRECTOR INDEMNIFICATION AGREEMENT This Indemnification Agreement (?Agreement?) is made as of [ ] by and between Axcella Health Inc., a Delaware corporation (the ?Company?), and [Director] (?Indemnitee?). RECITALS WHEREAS, the Company desires to attract and retain the services of highly qualified individuals, such as Indemnitee, to serve the Company; WHER
April 12, 2019	EX-10.7	Amended and Restated Employment Agreement between the Registrant and Stephen Mitchener, dated July 23, 2018 Exhibit 10.7 July 23, 2018 Mr. Stephen Mitchener Re: Offer of Employment Dear Stephen, On behalf of Axcella Health Inc. (the ?Company? or ?Axcella?) and the entire Board of Directors of the Company (the ?Board?), I am delighted to offer you employment with the Company. This offer letter agreement (the ?Agreement?) describes the initial terms and conditions of such employment. Your employment terms
April 12, 2019	EX-10.6	Amended and Restated Employment Agreement between the Registrant and Thomas Leggett, dated December 14, 2016 EX-10.6 8 a2238344zex-106.htm EX-10.6 Exhibit 10.6 December 14, 2016 BY EMAIL Mr. Thomas Leggett Re: Employment Agreement Dear Tom: On behalf of Axcella Health Inc. (the “Company”), and the entire Board of Directors of the Company (the “Board”), I am delighted to offer you employment with the Company. This offer letter agreement (the “Agreement”) describes the terms and conditions of such employme
April 12, 2019	EX-21.1	Subsidiaries of the Registrant Exhibit 21.1 Subsidiaries of the Registrant Entity Jurisdiction of Incorporation or Organization Acora Nutrition LLC Delaware Axcella Health Securities Corporation Massachusetts
April 12, 2019	EX-3.6	Bylaws of the Registrant, as currently in effect Exhibit 3.6 AMENDED AND RESTATED BYLAWS of Essentient, Inc. (f/k/a Newco LS16, Inc.) (the ?Corporation?) Article I - Stockholders 1. Annual Meeting. The annual meeting of stockholders shall be held for the election of directors each year at such place, date and time as shall be designated by the Board of Directors of the Corporation (the ?Board of Directors?). Any other proper business may be tran
April 12, 2019	EX-4.3	Fifth Amended and Restated Voting Agreement among the Registrant and certain of its stockholders, dated November 30, 2018 Exhibit 4.3 AXCELLA HEALTH INC. FIFTH AMENDED AND RESTATED VOTING AGREEMENT This FIFTH AMENDED AND RESTATED VOTING AGREEMENT is made and entered into as of this 30th day of November, 2018 by and among Axcella Health Inc., a Delaware corporation (the ?Company?), each holder of the Company?s Series A Preferred Stock, $0.001 par value per share (?Series A Preferred Stock?), each holder of the Company
April 12, 2019	EX-10.5	Amended and Restated Employment Agreement between the Registrant and William Hinshaw, dated April 18, 2018 Exhibit 10.5 April 18, 2018 William R. Hinshaw, Jr. Dear William: On behalf of Axcella Health, Inc. (the ?Company?), I am delighted to offer you employment with the Company. This offer letter (the ?Offer Letter?) and the accompanying documents and agreements summarize and set forth important terms about your employment with the Company. 1. Starting Date, Position, and Duties. a. Your initial posit
April 12, 2019	EX-10.9	Form of Indemnification Agreement between the Registrant and each of its executive officers (incorporated by reference to Exhibit 10.9 to the Registrant’s Registration Statement on Form S-1 (File No. 333-230822) filed with the Securities and Exchange Commission on April 12, 2019). Exhibit 10.9 AXCELLA HEALTH INC. [FORM OF] OFFICER INDEMNIFICATION AGREEMENT This Indemnification Agreement (?Agreement?) is made as of [ ] by and between Axcella Health Inc., a Delaware corporation (the ?Company?), and [Officer] (?Indemnitee?).(1) RECITALS WHEREAS, the Company desires to attract and retain the services of highly qualified individuals, such as Indemnitee, to serve the Company; WHE
April 12, 2019	S-1	Power of Attorney (included on the signature page hereto) Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS 2 Table of Contents As filed with the Securities and Exchange Commission on April 12, 2019 Registration No.
April 12, 2019	EX-3.1	Amended and Restated Certificate of Incorporation of the Registrant, as currently in effect Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF AXCELLA HEALTH INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Axcella Health Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the ?General Corporation Law?), DOES HEREBY CERTIFY: 1. That the name o
April 12, 2019	EX-4.4	Fifth Amended and Restated Right of First Refusal and Co-Sale Agreement among the Registrant and certain of its stockholders, dated November 30, 2018, as amended Exhibit 4.4 AXCELLA HEALTH INC. FIFTH AMENDED AND RESTATED RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT This FIFTH AMENDED AND RESTATED RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT is made as of November 30, 2018 by and among Axcella Health Inc., a Delaware corporation (the ?Company?), the Investors listed on Schedule A and any subsequent purchasers of Preferred Stock who become parties hereto as
March 15, 2019	DRS/A	As confidentially submitted to the Securities and Exchange Commission on March 15, 2019 as Amendment No. 1 to the Confidential Submission dated January 28, 2019. Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS 2 Table of Contents As confidentially submitted to the Securities and Exchange Commission on March 15, 2019 as Amendment No.
March 15, 2019	DRSLTR	AXLA / Axcella Health Inc. DRSLTR - - Goodwin Procter LLP 100 Northern Avenue Boston, MA 02210 goodwinlaw.com +1 617 570 1000 March 15, 2019 Mr. David Plattner Mr. Tom Kluck Office of Healthcare and Insurance Division of Corporation Finance Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Axcella Health Inc. Draft Registration Statement on Form S-1 Submitted January 28, 2019 CIK No. 0001633070 Dear Mr.
January 28, 2019	DRS	As confidentially submitted to the Securities and Exchange Commission on January 28, 2019. Use these links to rapidly review the document TABLE OF CONTENTS AXCELLA HEALTH INC.

AXLA / Axcella Health Inc. - Документы SEC, Годовой отчет, Доверенное заявление

Основная статистика

SEC Filings

SEC Filings (Chronological Order)